Top

Orphanet Journal of Rare Diseases

Published in:

Open Access 01-12-2023 | Epilepsy | Review

The burden of illness in Lennox–Gastaut syndrome: a systematic literature review

Authors: Adam Strzelczyk, Sameer M. Zuberi, Pasquale Striano, Felix Rosenow, Susanne Schubert-Bast

Published in: Orphanet Journal of Rare Diseases | Issue 1/2023

Abstract

Background

Lennox–Gastaut syndrome (LGS) is a severe developmental and epileptic encephalopathy characterized by drug-resistant epilepsy with multiple seizure types starting in childhood, a typical slow spike-wave pattern on electroencephalogram, and cognitive dysfunction.

Methods

We performed a systematic literature review according to the PRISMA guidelines to identify, synthesize and appraise the burden of illness in LGS (including “probable” LGS). Studies were identified by searching MEDLINE, Embase and APA PsychInfo, Cochrane’s database of systematic reviews, and Epistemonikos. The outcomes were epidemiology (incidence, prevalence or mortality), direct and indirect costs, healthcare resource utilization, and patient and caregiver health-related quality of life (HRQoL).

Results

The search identified 22 publications evaluating the epidemiology (n = 10), direct costs and resource (n = 10) and/or HRQoL (n = 5). No studies reporting on indirect costs were identified. With no specific ICD code for LGS in many regions, several studies had to rely upon indirect methods to identify their patient populations (e.g., algorithms to search insurance claims databases to identify “probable” LGS). There was heterogeneity between studies in how LGS was defined, the size of the populations, ages of the patients and length of the follow-up period. The prevalence varied from 4.2 to 60.8 per 100,000 people across studies for probable LGS and 2.9–28 per 100,000 for a confirmed/narrow definition of LGS. LGS was associated with high mortality rates compared to the general population and epilepsy population. Healthcare resource utilization and direct costs were substantial across all studies. Mean annual direct costs per person varied from $24,048 to $80,545 across studies, and home-based care and inpatient care were significant cost drivers. Studies showed that the HRQoL of patients and caregivers was adversely affected, although only a few studies were identified. In addition, studies suggested that seizure events were associated with higher costs and worse HRQoL. The risk of bias was low or moderate in most studies.

Conclusions

LGS is associated with a significant burden of illness featuring resistant seizures associated with higher costs and worse HRQoL. More research is needed, especially in evaluating indirect costs and caregiver burden, where there is a notable lack of studies.

Available only for authorised users

Lennox WG, Davis JP. Clinical correlates of the fast and the slow spike-wave electroencephalogram. Pediatrics. 1950;5(4):626–44.CrossRefPubMed

Gastaut H, Roger J, Soulayrol R, et al. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox syndrome. Epilepsia. 1966;7(2):139–79. https://doi.org/10.1111/j.1528-1167.1966.tb06263.x.CrossRefPubMed

Arzimanoglou A, French J, Blume WT, et al. Lennox–Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93. https://doi.org/10.1016/s1474-4422(08)70292-8.CrossRefPubMed

Camfield PR. Definition and natural history of Lennox–Gastaut syndrome. Epilepsia. 2011;52(s5):3–9. https://doi.org/10.1111/j.1528-1167.2011.03177.x.CrossRefPubMed

Cross JH, Auvin S, Falip M, et al. Expert opinion on the management of Lennox–Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol. 2017;8:505. https://doi.org/10.3389/fneur.2017.00505.CrossRefPubMedPubMedCentral

Kerr M, Kluger G, Philip S. Evolution and management of Lennox–Gastaut syndrome through adolescence and into adulthood: Are seizures always the primary issue? Epileptic Disord. 2011;13(Suppl 1):S15-26. https://doi.org/10.1684/epd.2011.0409.CrossRefPubMed

Yagi K. Evolution of Lennox–Gastaut syndrome: a long-term longitudinal study. Epilepsia. 1996;37(Suppl 3):48–51. https://doi.org/10.1111/j.1528-1157.1996.tb01821.x.CrossRefPubMed

Asadi-Pooya AA, Bazrafshan M, Farazdaghi M. Long-term medical and social outcomes of patients with Lennox–Gastaut syndrome. Epilepsy Res. 2021;178:106813. https://doi.org/10.1016/j.eplepsyres.2021.106813.CrossRefPubMed

Asadi-Pooya AA, Bazrafshan M, Farazdaghi M. Cluster analysis of a large dataset of patients with Lennox–Gastaut syndrome. Seizure. 2021;92:36–9. https://doi.org/10.1016/j.seizure.2021.08.005.CrossRefPubMed

10.

Asadi-Pooya AA, Farazdaghi M. Age at onset in patients with Lennox–Gastaut syndrome: correlations with clinical manifestations. J Clin Neurosci. 2022;100:138–42. https://doi.org/10.1016/j.jocn.2022.04.020.CrossRefPubMed

11.

Piña-Garza JE, Chung S, Montouris GD, et al. Challenges in identifying Lennox–Gastaut syndrome in adults: a case series illustrating its changing nature. Epilepsy Behav Case Rep. 2016;5:38–43. https://doi.org/10.1016/j.ebcr.2016.01.004.CrossRefPubMedPubMedCentral

12.

Riney K, Bogacz A, Somerville E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1443–74. https://doi.org/10.1111/epi.17240.CrossRefPubMed

13.

Asadi-Pooya AA. Lennox–Gastaut syndrome: a comprehensive review. Neurol Sci. 2018;39(3):403–14. https://doi.org/10.1007/s10072-017-3188-y.CrossRefPubMed

14.

Montouris G, Aboumatar S, Burdette D, et al. Expert opinion: proposed diagnostic and treatment algorithms for Lennox–Gastaut syndrome in adult patients. Epilepsy Behav. 2020;110:107146. https://doi.org/10.1016/j.yebeh.2020.107146.CrossRefPubMed

15.

Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for Lennox–Gastaut syndrome: current and future strategies. CNS Drugs. 2021;35(1):61–83. https://doi.org/10.1007/s40263-020-00784-8.CrossRefPubMedPubMedCentral

16.

Varadkar S. Cannabidiol for drop seizures in Lennox–Gastaut syndrome. Lancet. 2018;391(10125):1006–7. https://doi.org/10.1016/S0140-6736(18)30135-1.CrossRefPubMed

17.

Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology. 2008;70(21):1950–8. https://doi.org/10.1212/01.wnl.0000303813.95800.0d.CrossRefPubMed

18.

Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. New Engl J Med. 1997;337(25):1807–12. https://doi.org/10.1056/NEJM199712183372504.CrossRefPubMed

19.

Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox–Gastaut syndrome. Neurology. 2011;77(15):1473–81. https://doi.org/10.1212/WNL.0b013e318232de76.CrossRefPubMed

20.

Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome. Neurology. 1999;52(9):1882–7. https://doi.org/10.1212/wnl.52.9.1882.CrossRefPubMed

21.

The Felbamate Study Group in Lennox–Gastaut S. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). New Engl J Med. 1993;328(1):29–33. https://doi.org/10.1056/NEJM199301073280105.CrossRef

22.

Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox–Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96. https://doi.org/10.1016/s0140-6736(18)30136-3.CrossRefPubMed

23.

Knupp KG, Scheffer IE, Ceulemans B, et al. Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox–Gastaut syndrome: a randomized clinical trial. JAMA Neurol. 2022;79(6):554-64. https://doi.org/10.1001/jamaneurol.2022.0829.CrossRefPubMedPubMedCentral

24.

Brown ML, Lipscomb J, Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91–113. https://doi.org/10.1146/annurev.publhealth.22.1.91.CrossRefPubMed

25.

Zöllner JP, Franz DN, Hertzberg C, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020;15(1):23. https://doi.org/10.1186/s13023-019-1258-3.CrossRefPubMedPubMedCentral

26.

Sullivan J, Deighton AM, Vila MC, et al. The clinical, economic, and humanistic burden of Dravet syndrome–a systematic literature review. Epilepsy Behav. 2022;130:108661. https://doi.org/10.1016/j.yebeh.2022.108661.CrossRefPubMed

27.

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097s.CrossRefPubMedPubMedCentral

28.

Royle P, Bain L, Waugh N. Systematic reviews of epidemiology in diabetes: finding the evidence. BMC Med Res Methodol. 2005;5(1):2. https://doi.org/10.1186/1471-2288-5-2.CrossRefPubMedPubMedCentral

29.

Centre for Reviews and Dissemination. NHS EED economics filter: MEDLINE (Ovid) York: CRD; 2010

30.

Suzy Paisley, Andrew Booth, Shaila Mensinkai. Chapter 12: health-related quality of life studies. 2005 [cited Jun 10 2020]. In: Etext on Health Technology Assessment (HTA) Information Resources [Internet]. [cited Jun 10 2020]. Available from: https://www.nlm.nih.gov/archive/20060905/nichsr/ehta/chapter12.html.

31.

CADTH. Strings Attached: CADTH's Database Search Filters 2021 [Available from: https://www.cadth.ca/strings-attached-cadths-database-search-filters.

32.

Cooper C, Booth A, Britten N, et al. A comparison of results of empirical studies of supplementary search techniques and recommendations in review methodology handbooks: a methodological review. Syst Rev. 2017;6(1):234. https://doi.org/10.1186/s13643-017-0625-1.CrossRefPubMedPubMedCentral

33.

Cooper C, Dawson S, Peters J, et al. Revisiting the need for a literature search narrative: a brief methodological note. Res Synth Methods. 2018;9(3):361–5. https://doi.org/10.1002/jrsm.1315.CrossRefPubMed

34.

Covidence. Systematic review management platform [Available from: https://www.covidence.org/]

35.

Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934–9. https://doi.org/10.1016/j.jclinepi.2011.11.014.CrossRefPubMed

36.

Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.

37.

Molinier L, Bauvin E, Combescure C, et al. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health. 2008;11(5):878–85. https://doi.org/10.1111/j.1524-4733.2008.00327.x.CrossRefPubMed

38.

Gallop K, Lloyd AJ, Olt J, et al. Impact of developmental and epileptic encephalopathies on caregivers: a literature review. Epilepsy Behav. 2021;124:108324. https://doi.org/10.1016/j.yebeh.2021.108324.CrossRefPubMed

39.

Beilmann A, Napa A, Soot A, et al. Prevalence of childhood epilepsy in Estonia. Epilepsia. 1999;40(7):1011–9.CrossRefPubMed

40.

Chin RFM, Pickrell WO, Guelfucci F, et al. Prevalence, healthcare resource utilization and mortality of Lennox–Gastaut syndrome: retrospective linkage cohort study. Seizure. 2021;91:159–66.CrossRefPubMed

41.

Hollenack K, Story T, Acs A, et al. Prevalence of probable dravet syndrome, Lennox–Gastaut syndrome, and other refractory epilepsies in commercial and medicaid populations in the United States. J Manag Care Spec Pharm. 2019;25(3-A SUPPL):S58.

42.

Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox–Gastaut syndrome. Epilepsia. 1999;40(3):286–9.CrossRefPubMed

43.

Sidenvall R, Forsgren L, Heijbel J. Prevalence and characteristics of epilepsy in children in northern Sweden. Seizure. 1996;5(2):139–46.CrossRefPubMed

44.

Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox–Gastaut syndrome among Atlanta children. Epilepsia. 1997;38(12):1283–8.CrossRefPubMed

45.

Heiskala H. Community-based study of Lennox–Gastaut syndrome. Epilepsia. 1997;38(5):526–31.CrossRefPubMed

46.

Pina-Garza JE, Montouris GD, Vekeman F, et al. Assessment of treatment patterns and healthcare costs associated with probable Lennox–Gastaut syndrome. Epilepsy Behav. 2017;73:46–50.CrossRefPubMed

47.

Strzelczyk A, Schubert-Bast S, Simon A, et al. Epidemiology, healthcare resource use, and mortality in patients with probable Lennox–Gastaut syndrome: a population-based study on German health insurance data. Epilepsy Behav. 2021;115: 107647.CrossRefPubMed

48.

Autry AR, Trevathan E, Van Naarden Braun K, et al. Increased risk of death among children with Lennox–Gastaut syndrome and infantile spasms. J Child Neurol. 2010;25(4):441–7.CrossRefPubMed

49.

Office for National Statistics (ONS). Death registrations, Populations and Age Standardised Rates, England 1981 to 2018 2020 [Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/11168deathregistrationspopulationsandagestandardisedratesengland1981to2018.]

50.

Myland M, Buysse B, Tsong W, et al. Seizure frequency, healthcare resource utilisation and mortality in childhood epilepsy: a retrospective cohort study using the THIN database. Arch Dis Child. 2019;104(11):1070. https://doi.org/10.1136/archdischild-2019-316910.CrossRefPubMed

51.

Francois C, Stern JM, Ogbonnaya A, et al. Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox–Gastaut syndrome. J Mark Access Health Policy. 2017;5(1):1318691.CrossRefPubMedPubMedCentral

52.

Hollenack KA, Story TJ, Acs A, et al. Pnd34 economic burden of probable Lennox–Gastaut syndrome, probable Dravet syndrome, and other refractory epilepsies for united states medicaid health plans. Value Health. 2019;22(Supplement 2):S276.CrossRef

53.

Reaven NL, Funk SE, Lyons PD, et al. The direct cost of seizure events in severe childhood-onset epilepsies: a retrospective claims-based analysis. Epilepsy Behav. 2019;93:65–72.CrossRefPubMed

54.

Reaven NL, Funk SE, Montouris GD, et al. Burden of illness in patients with possible Lennox–Gastaut syndrome: a retrospective claims-based study. Epilepsy Behav. 2018;88:66–73.CrossRefPubMed

55.

Stockl KM, Hollenack KA, Acs A, et al. Pnd27 economic burden of probable Lennox–Gastaut syndrome, probable Dravet syndrome, and other refractory epilepsies for united states commercial health plans. Value Health. 2019;22(Supplement 2):S274.CrossRef

56.

Stockl K, Funk S, Reaven N, et al. Inpatient hospitalizations and readmissions among patients with probable Lennox–Gastaut syndrome, dravet syndrome, tuberous sclerosis complex, and other refractory epilepsies. J Manag Care Spec Pharm. 2019;25(10-A SUPPL):S57–8.

57.

Umeno J. A survey on the utilization status of social welfare services for pediatric patients with epilepsy. [Japanese]. No To Hattatsu. 2019;51(4):23–49.

58.

Gallop K, Wild D, Verdian L, et al. Lennox–Gastaut Syndrome (LGS): development of conceptual models of health-related quality of life (HRQL) for caregivers and children. Seizure. 2010;19(1):23–30.CrossRefPubMed

59.

Gibson PA. Lennox–Gastaut syndrome: impact on the caregivers and families of patients. J Multidiscip Healthc. 2014;7:441–8.CrossRefPubMedPubMedCentral

60.

Murray J. Coping with the uncertainty of uncontrolled epilepsy. Seizure. 1993;2(3):167–78.CrossRefPubMed

61.

Auvin S, Damera V, Martin M, et al. The impact of seizure frequency on quality of life in patients with Lennox–Gastaut syndrome or Dravet syndrome. Epilepsy Behav. 2021;123: 108239.CrossRefPubMed

62.

Radu X, Damera V, Martin M, et al. Pro58 quality of life in patients with Dravet syndrome or Lennox Gastaut syndrome in the Uk: higher seizure frequency has a substantial negative impact on quality of life. Value Health. 2019;22(Supplement 2):S346.CrossRef

63.

National Institute for Health And Care Excellence (NICE). Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome 2019 [Available from: https://www.nice.org.uk/guidance/ta615/documents/final-appraisal-determination-document]

64.

World Health Organization. International Classification of Diseases 11th Revision (ICD-11) 2022 [Available from: https://www.who.int/standards/classifications/classification-of-diseases]

65.

Vekeman F, Piña-Garza JE, Cheng WY, et al. Development of a classifier to identify patients with probable Lennox–Gastaut syndrome in health insurance claims databases via random forest methodology. Curr Med Res Opin. 2019;35(8):1415–20. https://doi.org/10.1080/03007995.2019.1595552.CrossRefPubMed

66.

Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox–Gastaut syndrome in the UK. Pharmacoeconomics. 2010;28(3):185–99.CrossRefPubMed

67.

Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox–Gastaut Syndrome in the United Kingdom. Seizure. 2010;19(1):1–11.CrossRefPubMed

68.

Wijnen B, Armstrong N, Ramaekers B, et al. Cannabidiol for adjuvant treatment of seizures associated with Lennox–Gastaut syndrome and dravet syndrome: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2020;38(10):1043–53.CrossRefPubMed

69.

Neuberger EE, Carlson JJ, Veenstra DL. Cost-effectiveness of cannabidiol adjunct therapy versus usual care for the treatment of seizures in Lennox–Gastaut syndrome. Pharmacoeconomics. 2020;38(11):1237–45.CrossRefPubMed

70.

Strzelczyk A, Kurlemann G, Bast T, et al. Exploring the relationships between composite scores of disease severity, seizure-freedom and quality of life in Dravet syndrome. Neurol Res Pract. 2022;4(1):22. https://doi.org/10.1186/s42466-022-00186-9.CrossRefPubMedPubMedCentral

71.

Lagae L, Brambilla I, Mingorance A, et al. Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey. Dev Med Child Neurol. 2018;60(1):63–72. https://doi.org/10.1111/dmcn.13591.CrossRefPubMed

72.

Strzelczyk A, Schubert-Bast S, Bast T, et al. A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany. Epilepsia. 2019;60(8):1697–710. https://doi.org/10.1111/epi.16099.CrossRefPubMed

73.

Strzelczyk A, Kalski M, Bast T, et al. Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany. Eur J Paediatr Neurol. 2019;23(3):392–403. https://doi.org/10.1016/j.ejpn.2019.02.014.CrossRefPubMed

74.

Grau J, Zöllner JP, Schubert-Bast S, et al. Direct and indirect costs and cost-driving factors of Tuberous sclerosis complex in children, adolescents, and caregivers: a multicenter cohort study. Orphanet J Rare Dis. 2021;16(1):282. https://doi.org/10.1186/s13023-021-01899-x.CrossRefPubMedPubMedCentral

75.

Sancho J, Peña P, Rufo M, et al. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: a cost-of-illness study (LINCE study). Epilepsy Res. 2008;81(2–3):176–87. https://doi.org/10.1016/j.eplepsyres.2008.05.008.CrossRefPubMed

76.

Zöllner JP, Grau J, Rosenow F, et al. Direct and indirect costs and cost-driving factors in adults with tuberous sclerosis complex: a multicenter cohort study and a review of the literature. Orphanet J Rare Dis. 2021;16(1):250. https://doi.org/10.1186/s13023-021-01838-w.CrossRefPubMedPubMedCentral

77.

Nabbout R, Dirani M, Teng T, et al. Impact of childhood Dravet syndrome on care givers of patients with DS, a major impact on mothers. Epilepsy Behav. 2020;108:107094. https://doi.org/10.1016/j.yebeh.2020.107094.CrossRefPubMed

78.

Harris M, Macinko J, Jimenez G, et al. Measuring the bias against low-income country research: an Implicit Association Test. Globalization Health. 2017;13(1):80. https://doi.org/10.1186/s12992-017-0304-y.CrossRefPubMedPubMedCentral

79.

Harris M, Marti J, Watt H, et al. Explicit bias toward high-income-country research: a randomized, blinded, crossover experiment of english clinicians. Health Aff. 2017;36(11):1997–2004. https://doi.org/10.1377/hlthaff.2017.0773.CrossRef

80.

Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80. https://doi.org/10.1016/S1474-4422(18)30499-X.CrossRef

81.

Singh G, Sander JW. The global burden of epilepsy report: implications for low-and middle-income countries. Epilepsy Behav. 2020;105:106949. https://doi.org/10.1016/j.yebeh.2020.106949.CrossRefPubMed

82.

Davies EH, Fieggen K, Wilmshurst J, et al. Demonstrating the feasibility of digital health to support pediatric patients in South Africa. Epilepsia Open. 2021;6(4):653–62. https://doi.org/10.1002/epi4.12527.CrossRefPubMedPubMedCentral

83.

Le VT, Le Thuy MA, Nguyen DH, et al. Epilepsy surgery program in a resource-limited setting in Vietnam: a multicentered collaborative model. Epilepsia Open. 2022;7(4):710–7. https://doi.org/10.1002/epi4.12650.10.1002/epi4.12650.CrossRefPubMedPubMedCentral

84.

Camfield P, Camfield C. Long-term prognosis for symptomatic (secondarily) generalized epilepsies: a population-based study. Epilepsia. 2007;48(6):1128–32.CrossRefPubMed

85.

Hahn CD, Jiang Y, Villanueva V, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA). Epilepsia. 2022;63(10):2671–83. https://doi.org/10.1111/epi.17367.CrossRefPubMedPubMedCentral

86.

Specchio N, Wirrell EC, Scheffer IE, et al. International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE task force on nosology and definitions. Epilepsia. 2022;63(6):1398–442. https://doi.org/10.1111/epi.17241.

87.

Offen ML. Dealing with “defectives” Foster Kennedy and William Lennox on eugenics. Neurology. 2003;61(5):668. https://doi.org/10.1212/WNL.61.5.668.CrossRefPubMed

88.

Rosso M, Chu D, Santoro JD. William Gordon Lennox (1884–1960). J Neurol. 2021;268(9):3512–3. https://doi.org/10.1007/s00415-020-10338-z.CrossRefPubMed

89.

Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs. 2022:36(10):1079–111. https://doi.org/10.1007/s40263-022-00955-9.

90.

Niedermeyer E. The Lennox–Gastaut syndrome: a severe type of childhood epilepsy. Dtsch Z Nervenheilkd. 1969;195(4):263–82. https://doi.org/10.1007/bf00242459.CrossRefPubMed

91.

Beaumanoir A, et al. The Lennox–Gastaut syndrome. In: Roger J, Bureau M, Dravet C, et al., editors. Epileptic syndromes in infancy, childhood, and adolescence. London: John Libbey; 1985. p. 89–99.

92.

International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy. Epilepsia. 1989;30(4):389–99. https://doi.org/10.1111/j.1528-1157.1989.tb05316.x.CrossRef

93.

Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology. Epilepsia. 2001;42(6):796–803. https://doi.org/10.1046/j.1528-1157.2001.10401.x.CrossRefPubMed

94.

Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–21. https://doi.org/10.1111/epi.13709.CrossRefPubMedPubMedCentral

95.

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71.CrossRefPubMedPubMedCentral

Title: The burden of illness in Lennox–Gastaut syndrome: a systematic literature review
Authors: Adam Strzelczyk
Sameer M. Zuberi
Pasquale Striano
Felix Rosenow
Susanne Schubert-Bast
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Epilepsy
Encephalopathy
Dravet Syndrome
Lennox Gastaut Syndrome
Published in: Orphanet Journal of Rare Diseases / Issue 1/2023
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-023-02626-4

2024 ASCO Annual Meeting

Springer Medicine

The burden of illness in Lennox–Gastaut syndrome: a systematic literature review

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

What we don't need to prove but need to do in multidisciplinary treatment and care in Huntington's disease: a position paper

Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis

C1-inhibitor/C1-inhibitor antibody complexes in acquired angioedema due to C1-inhibitor deficiency

Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022

Association of preoperative retinal microcirculation and perioperative outcomes in patients undergoing congenital cardiac surgery

ORPHAcodes use for the coding of rare diseases: comparison of the accuracy and cross country comparability